Equities Analysts Set Expectations for Zoetis Inc’s Q1 2017 Earnings (ZTS)
Zoetis Inc (NYSE:ZTS) – Investment analysts at William Blair decreased their Q1 2017 EPS estimates for Zoetis in a research note issued to investors on Friday. William Blair analyst J. Kreger now forecasts that the brokerage will earn $0.49 per share for the quarter, down from their prior estimate of $0.52. William Blair also issued estimates for Zoetis’ Q2 2017 earnings at $0.53 EPS and Q4 2017 earnings at $0.65 EPS.
Other equities analysts have also issued research reports about the company. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a research note on Thursday, December 29th. Guggenheim reissued a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research note on Friday, December 23rd. Deutsche Bank AG started coverage on Zoetis in a research note on Tuesday, December 20th. They issued a “buy” rating and a $62.00 price target on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $62.00 price target on shares of Zoetis in a research note on Tuesday, December 20th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $60.00 price target on shares of Zoetis in a research note on Wednesday, February 8th. Three analysts have rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $57.12.
Your IP Address:
Zoetis (NYSE:ZTS) opened at 54.28 on Monday. Zoetis has a 1-year low of $39.80 and a 1-year high of $56.50. The firm has a 50-day moving average price of $54.25 and a 200 day moving average price of $52.11. The stock has a market cap of $26.70 billion, a price-to-earnings ratio of 32.90 and a beta of 1.07.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 16th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.02. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the previous year, the firm earned $0.43 earnings per share. The firm’s quarterly revenue was up .2% compared to the same quarter last year.
Institutional investors have recently bought and sold shares of the company. Mason Street Advisors LLC purchased a new position in Zoetis during the second quarter valued at about $2,918,000. Kentucky Retirement Systems purchased a new position in Zoetis during the second quarter valued at about $1,842,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new position in Zoetis during the second quarter valued at about $875,000. Williams Jones & Associates LLC raised its position in Zoetis by 2,171.9% in the second quarter. Williams Jones & Associates LLC now owns 15,903 shares of the company’s stock valued at $755,000 after buying an additional 15,203 shares during the last quarter. Finally, Macquarie Group Ltd. raised its position in Zoetis by 440.6% in the second quarter. Macquarie Group Ltd. now owns 90,200 shares of the company’s stock valued at $4,281,000 after buying an additional 73,516 shares during the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Investors of record on Thursday, April 6th will be paid a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a yield of 0.77%. The ex-dividend date is Tuesday, April 4th. Zoetis’s payout ratio is 30.44%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.